Drug
Sirukumab clinical trials
Also written CNTO 136.
- studies test it
- 15
- open now
- 0
- in phase 3
- 7
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
15 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Janssen Research & Development, LLC (8) · GlaxoSmithKline (3) · Centocor, Inc. (2) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen Pharmaceutical K.K. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses sirukumab is read from its arms, and is right about nine times in ten.
Testing it · 15
- An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive DisorderCompletedPhase 2Janssen Research & Development, LLCNCT02473289Written as Sirukumab 50 mg
- A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19CompletedPhase 2Janssen Pharmaceutica N.V., BelgiumNCT04380961Written as Sirukumab
- Efficacy and Safety Study of Sirukumab in Patients With Giant Cell ArteritisTerminatedPhase 3GlaxoSmithKlineNCT02531633Written as Sirukumab
- Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003CompletedPhase 3Janssen Research & Development, LLCNCT01856309Written as Sirukumab 100 mg
- A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled AsthmaWithdrawnPhase 2GlaxoSmithKlineNCT02794519Written as Sirukumab
- A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)CompletedPhase 3Janssen Research & Development, LLCNCT01606761Written as Sirukumab
- A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyCompletedPhase 2Centocor, Inc.NCT00718718Written as CNTO 136 100 mg
- A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)CompletedPhase 3Janssen Research & Development, LLCNCT01604343Written as Sirukumab
- Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia RheumaticaWithdrawnPhase 3GlaxoSmithKlineNCT02899026Written as Sirukumab
- A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid ArthritisCompletedPhase 3Janssen Research & Development, LLCNCT02019472Written as sirukumab 100 mg
- A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid ArthritisCompletedPhase 1Janssen Research & Development, LLCNCT01636557Written as Sirukumab
- A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or SulfasalazineCompletedPhase 3Janssen Pharmaceutical K.K.NCT01689532Written as Sirukumab 100 mg
- An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus NephritisCompletedPhase 2Janssen Research & Development, LLCNCT01273389Written as CNTO 136
- Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02079545Written as Sirukumab (IV infusion)
- A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian VolunteersCompletedPhase 1Centocor, Inc.NCT00844909Written as CNTO 136
Codes
What other systems call sirukumab · ClinicalTrials.gg INT005957
- MeSH (NLM) C568922sirukumabOne source NLM
- UNII (FDA) 640443FU93SIRUKUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7530673sirukumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152371SirukumabOne source FDA
- DrugBank DB11803One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C568922 | sirukumab | One source NLM |
| UNII (FDA) | 640443FU93 | SIRUKUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7530673 | sirukumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152371 | Sirukumab | One source FDA |
| DrugBank | DB11803 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.